GE Healthcare has announced a research collaboration with Japanese pharmaceutical firm Eisai.
Eisai will use GE's F-18 flutemetamol investigational PET agent to help select patients for a phase I clinical trial, according to GE. The trial will evaluate Eisai's investigational compound E2609, a beta-site amyloid precursor protein-cleaving enzyme (BACE) inhibitor for the potential treatment of Alzheimer's disease, GE said.
